title: Oral arsenic treatment of leukemia and the risk of porphyria.
authors.forename: Wing-Yan
authors.initials: WY
authors.lastname: Au
authors.forename: Sidney
authors.initials: S
authors.lastname: Tam
authors.forename: Bonnie M
authors.initials: BM
authors.lastname: Fong
authors.forename: Yok-Lam
authors.initials: YL
authors.lastname: Kwong
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects*; D011164:Porphyrias / Q000139:chemically induced*; D011166:Porphyrins / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D011166:Porphyrins; D000077237:Arsenic Trioxide